Anders Hougaard

Anders Hougaard

Auto-generated profile, based on publicly available information

Anders Hougaard

Department of Neurology, Copenhagen University Hospital – Herlev and Gentofte, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2021 in Brain
Verified
Journal Article
Open access
PDF file
MAMohammad Al-Mahdi Al-Karagholi
Mohammad Al-Mahdi Al-Karagholi
HGHashmat Ghanizada
Hashmat Ghanizada
CNCherie Amalie Waldorff Nielsen
Cherie Amalie Waldorff Nielsen
AHAnders Hougaard
Anders Hougaard
MAMessoud Ashina
Messoud Ashina
Migraine afflicts more than one billion individuals worldwide and is a leading cause of years lived with disability. In about a third of individuals with migraine aura occur in relation to migraine headache. The common pathophysiological mechanisms underlying migraine headache and migraine aura are yet to be identified. Based on recent data, we hypothesized that levcromakalim, an ATP-sensitive potassium channel opener, would trigger migraine attacks with aura in patients. In a randomized, double-blind, placebo-controlled, crossover study, 17 patients aged 21–59 years and diagnosed with migraine with aura exclusively were randomly allocated to receive an infusion of 0.05 mg/min levcromakalim or placebo (isotonic saline) on two different days (ClinicalTrials.gov, ID: NCT04012047). The primary end points were the difference in incidence of migraine attacks with or without aura, headache and the difference in the area under the curve for headache intensity scores (0–12 h). Seventeen patients completed the study. Fourteen of 17 (82%) patients developed migraine attacks with and without aura after levcromakalim compared with 1 of 17 (6%) after placebo (P < 0.001). Ten patients (59%) developed migraine with aura after levcromakalim compared with none after placebo (P = 0.002). One additional patient reported ‘possible’ aura, only partially fulfilling the criteria. Levcromakalim is likely a novel migraine aura-inducing substance in humans. These findings highlight the ATP-sensitive potassium channel as a shared target in migraine aura and migraine headache. Likely, ATP-sensitive potassium channel opening leads to triggering of aura and headache, respectively, via distinct mechanisms.

27 February 2017 in Human Brain Mapping
Verified
Journal Article
Closed access
PDF file
AHAnders Hougaard
Anders Hougaard
FAFaisal Mohammad Amin
Faisal Mohammad Amin
HLHenrik B.W. Larsson
Henrik B.W. Larsson
EREgill Rostrup
Egill Rostrup
MAMessoud Ashina
Messoud Ashina

20 July 2017 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
FAFaisal Mohammad Amin
Faisal Mohammad Amin
AHA. Hougaard
A. Hougaard
SCS. P. Cramer
S. P. Cramer
CCCasper Christensen
Casper Christensen
FWF. Wolfram
F. Wolfram
MAM. Ashina
M. Ashina

12 April 2024 in Expert Opinion on Pharmacotherapy
Verified
Journal Article
Open access
LPLanfranco Pellesi
Lanfranco Pellesi
TDThien Phu Do
Thien Phu Do
AHAnders Hougaard
Anders Hougaard
1. Migraine is a common neurological disorder that affects a considerable portion of the global population, leading to significant individual and societal burdens. It is characterized by recurrent ...

11 November 2017 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
NANanna Arngrim
Nanna Arngrim
AHAnders Hougaard
Anders Hougaard
KAKhazar Ahmadi
Khazar Ahmadi
MVMark Bitsch Vestergaard
Mark Bitsch Vestergaard
HSHenrik Schytz
Henrik Schytz
MAMessoud Ashina
Messoud Ashina

9 January 2015 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
AHA. Hougaard
A. Hougaard
FAFaisal Mohammad Amin
Faisal Mohammad Amin
SMS. Magon
S. Magon
TST. Sprenger
T. Sprenger
ERE. Rostrup
E. Rostrup
MAM. Ashina
M. Ashina